Conyers acted as Bermuda advisors to Roivant Sciences Ltd. in connection with the sale of Dermavant Sciences Ltd. to Organon & Co. Dermavant is a Roivant subsidiary dedicated to developing and commercialising innovative therapeutics in immuno-dermatology. Organon agreed to acquire Dermavant for aggregate consideration of up to approximately US$1.2 billion.

Conyers Bermuda Directors Neil Henderson, Robert Alexander and Senior Associate Jessica Harris acted alongside Freshfields Bruckhaus Deringer for Roivant.

Stay current with our latest legal insights and subscribe today